Background: The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) revolutionized the understanding of lipoprotein metabolism (1) . Rapid translation of genetic insights led to the development of a new class of therapeutic agents that antagonize plasma PCSK9 and cause remarkable reductions (between 45% and 75%) in low-density lipoprotein (LDL) cholesterol levels. A large randomized controlled trial recently showed that adding a PCSK9 inhibitor in patients with established vascular disease who were already treated with optimized statin therapy caused statistically significant reductions in rates of myocardial infarction and stroke (2) . Most patients receiving a PCSK9 inhibitor respond with marked reductions in LDL cholesterol levels, but some exhibit a reduced or even absent lipid-lowering response that may be due to many factors, including poor adherence or PCSK9 inhibitor resistance.
Objective: To describe changes in plasma PCSK9 levels before and after PCSK9 inhibitor therapy in a series of adult patients with and without the anticipated reduction in LDL cholesterol levels.
Methods and Findings:
We studied 17 adults with cardiovascular disease (n = 14) and/or familial hypercholesterolemia (n = 9) who were treated with a PCSK9 inhibitor (12 patients received alirocumab and 5 patients received evolocumab) (Table) . All patients except patient 11 were also treated with other agents, such as a statin, ezetimibe, -3 fatty acids, or niacin; 10 patients had statin intolerance. Total plasma PCSK9 levels were measured before and 3 months after initiation of PCSK9 inhibitor therapy by using a commercially available human PCSK9 enzyme-linked immunosorbent assay (R&D Systems) according to the manufacturer's instruction. The mean baseline plasma PCSK9 level was 324 ng/mL (SD, 117). Total plasma PCSK9 levels in patients receiving therapy were also measured within 5 days of their sixth self-injection of the PCSK9 inhibitor. The mean plasma PCSK9 level at this time among patients with the anticipated greater-than-45% reduction in LDL cholesterol levels (patients 1 through 15 in the Table) was 2286 ng/mL (SD, 715), a median 7-fold increase from baseline levels. Although responses varied, plasma PCSK9 levels in patients 1 through 16 increased by at least 3.7-fold and none of the 16 patients had overlapping pre-and posttreatment values.
The response of LDL cholesterol levels to the PCSK9 inhibitor was markedly attenuated in 2 of the 9 patients with heterozygous familial hypercholesterolemia (diagnosed on clinical grounds). One of these patients (patient 16 in the Table) had a 10.3% reduction in LDL cholesterol levels and a 9.49-fold increase in plasma PCSK9 levels. This finding suggests that the antibody reached the circulation, bound to PCSK9, and blocked its clearance but only minimally affected LDL cholesterol clearance. The second patient (patient 17 in the Table) had a 14% reduction in LDL cholesterol levels and no change in plasma PCSK9 levels, suggesting that the antibody did not reach the circulation, was disposed of too quickly, or failed to bind to plasma PCSK9.
Discussion: Although most patients treated with PCSK9 inhibitors respond with marked reductions in LDL cholesterol levels, some exhibit a reduced or even absent lipid-lowering response (3) . Clinicians who encounter patients with an unanticipated lack of response to the expensive PCSK9 inhibitor regimen previously had few options to investigate the cause of nonresponse. We report a simple method for assessing apparent resistance by measuring total levels of plasma PCSK9 before and after treatment. The monoclonal antibody acts as a PCSK9 inhibitor; however, it inhibits the function of PCSK9 and not its plasma levels, which are instead increased by binding to the monoclonal antibody.
Our findings suggest that a PCSK9 inhibitor induces a compensatory increase in PCSK9 production or, more likely, the monoclonal antibody-PCSK9 complexes delay plasma PCSK9 clearance, which is expected given that PCSK9 is cleared via the LDL cholesterol receptor pathway (4). Consistently large increases in total plasma levels during PCSK9 inhibitor therapy may confirm adherence to therapy in patients with the expected reductions in LDL cholesterol levels and help identify the rare cases of PCSK9 inhibitor resistance in those with reductions of less than 15%. In patients prescribed PCSK9 inhibitors, the absence of a marked elevation in total plasma levels (as in patient 17 in the Table) suggests lack of adherence, poor injection technique, dermatologic conditions interfering with monoclonal antibody entry into the circulation, inappropriate antibody disposition, mutations in PCSK9 that change the monoclonal antibody recognition site, or autoantibody production against the injected monoclonal antibody. Poor or no response to PCSK9 inhibitor therapy and an elevated plasma level (as in patient 16 in the Table) proves that drug administration was appropriate and that the monoclonal antibody engaged its target in the circulation, thus setting the stage for the investigations of mechanistic causes of PCSK9 inhibitor resistance (such as dysfunctional mutations of PCSK9, the LDL cholesterol receptor, or apolipoprotein E or B). 
CORRESPONDENCE Coffee Drinking and Mortality in 10 European Countries

TO THE EDITOR:
We believe that there are 2 potential threats to the validity of Gunter and colleagues' (1) and Park and associates' (2) studies. Daily coffee intake usually begins at approximately 20 years of age in the context of adult student life or incorporation into the job market. Nevertheless, the median age at baseline in both studies was older than 50 years. Persons from the source populations may thus have been exposed to coffee for a median of 30 years before study entry. This prevalent user design may have allowed for a decrease in the number of susceptible persons (who may have had events before qualifying for study entry) from the coffee intake groups, resulting in an exposed study population of healthy survivors. Incident user designs-that is, those that are exposure-naive-are considered the gold standard in observational pharmacoepidemiology, because the selection bias derived from inclusion of prevalent users is minimized and the associations are more consistent with those from randomized trials (3). Of interest, in an analysis of the Johns Hopkins Precursors Study by Klag and colleagues (4) in which the baseline age was younger than 30 years (that is, closer to an incident user design), there was a strong association between coffee use and cardiovascular events in multivariable analyses. The risk for residual confounding is also worth mentioning. Socially conditioned behaviors, such as coffee intake, are particularly challenging and subject to confounding by socioeconomic status (SES). As with studies of moderate alcohol consumption, these behaviors are strongly prevalent in groups with higher SES, and higher SES in itself is a protective factor for health outcomes (5) . Although the authors did adjust for education, SES is a complex, latent construct for which proxies (such as education, income, or occupation) are often measured erroneously when measured at all and may not fully capture the effect of SES. Of note, Gunter and colleagues' (1) sensitivity analysis assessing robustness to residual confounding found that a risk factor with a hazard ratio of 1.50 (within the realm of the feasible effect sizes of poverty [5] ) needs only a 20% difference in the confounder between groups.
Because of these limitations, we believe that the reports of these studies in the lay press may have exaggerated their causal significance. Future research on coffee intake and health should aim to include younger persons and use more comprehensive measurements of SES.
